Application of melatonin in the preparation of drugs for delaying the risk of phenotypic transformation in patients with isolated REM sleep behavior disorder
By preparing melatonin into an oral formulation for iRBD patients, the problem of the lack of existing technologies in reducing the risk of phenotypic transformation of neurodegenerative diseases has been solved, and the effects of significantly reducing the risk of iRBD patients transforming into α-synucleinosis-related diseases and delaying related symptoms have been achieved.
Patent Information
- Application Number
- CN202610977784.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-07-02
- Publication Date
- 2026-11-10
AI Technical Summary
In the prior art, melatonin is mainly used to improve short-term symptoms such as dream enactment behavior and sleep quality in patients with rapid eye movement sleep behavior disorder (RBD), but it lacks a use in reducing the risk of isolated rapid eye movement sleep behavior disorder (iRBD) patients to develop neurodegenerative disease phenotypes.
Melatonin is used as the active ingredient to prepare an oral formulation for iRBD patients, with long-term use to reduce their phenotypic risk of alpha-synucleinopathy-related neurodegenerative diseases such as Parkinson's disease and Lewy body dementia.
Continuous use of melatonin significantly reduces the risk of transformation to neurodegenerative diseases in patients with iRBD, particularly the probability of developing Lewy body dementia, and slows the progression of related clinical manifestations and biomarkers.
Smart Images

Figure CN123059040A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the pharmaceutical field, specifically to the use of melatonin in the preparation of a drug for delaying the risk of phenotypic transformation in patients with isolated REM sleep behavior disorder. Background Technology
[0002] Rapid eye movement sleep behavior disorder (RBD) is a sleep disorder that occurs during rapid eye movement (REM) sleep. Its typical characteristic is the loss of normal muscle tone inhibition during REM sleep, accompanied by dream enactment behaviors. Patients may exhibit shouting, limb flailing, kicking, or falling out of bed during sleep, which can lead to injury to the patient or their bed partner in severe cases. Isolated rapid eye movement sleep behavior disorder (iRBD) refers to a condition where the patient meets the diagnostic criteria for RBD but has not yet been diagnosed with a clear neurodegenerative disease.
[0003] Inflammatory renal disease (iRBD) is not only a sleep disorder but is also considered an important precursor to alpha-synucleinopathy-related neurodegenerative diseases. Some iRBD patients may gradually undergo phenotypic transformation during long-term follow-up, progressing to diseases such as Parkinson's disease, Lewy body dementia, or multiple system atrophy. Therefore, iRBD patients not only face the risk of nocturnal sleep behavior abnormalities and sleep-related impairments but also the risk of long-term neurodegenerative disease phenotypic transformation. For these patients, clinical needs should not be limited to improving nocturnal symptoms but also include exploring early intervention programs that can reduce or delay the risk of long-term neurodegenerative disease phenotypic transformation.
[0004] Currently, the clinical management of iRBD primarily focuses on symptom management, including sleep environment safety management and pharmacological intervention. Commonly used drugs include clonazepam and melatonin. Clonazepam can be used to reduce dream enactment behavior, but in elderly patients or those with cognitive impairment, there may be concerns about its use due to drowsiness, falls, and cognitive impairment. Melatonin is an endogenous hormone related to circadian rhythm regulation and sleep regulation. Clinically, it is often used to improve sleep-related symptoms in RBD patients, exhibiting relatively good safety and tolerability, and therefore has a certain foundation for application in RBD symptom management.
[0005] However, current technology only uses melatonin as a symptomatic treatment to improve RBD symptoms, lacking a clear purpose for reducing the long-term risk of phenotypic transformation. Although iRBD patients are not diagnosed with neurodegenerative diseases such as Parkinson's disease, Lewy body dementia, or multiple system atrophy at the onset of the disease, this population itself has a high risk of alpha-synucleinopathy-related phenotypic transformation. Existing melatonin regimens typically focus on whether the patient's nighttime symptoms are alleviated, without considering the risk of phenotypic transformation.
[0006] Patent text CN120548180A discloses the application of N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-4-oxo-4H-pyran-2-carboxamide (piromeratin) to RBD patients to delay or prevent phenotypic transformation to synucleinopathic Parkinson's disease and chronic PTSD, but does not involve related phenotypic transformations such as Lewy body dementia. Summary of the Invention
[0007] In the prior art, melatonin is mainly used for short-term symptom control purposes such as improving dream performance behavior, reducing sleep-related damage, and improving sleep quality. This invention uses the phenotypic transformation of neurodegenerative diseases as the primary observation endpoint. Based on long-term follow-up studies, it has been found that melatonin can reduce the risk of iRBD patients undergoing phenotypic transformation to related neurodegenerative diseases.
[0008] Therefore, in a first aspect, the present invention provides the use of melatonin in the preparation of a medicament for delaying the risk of phenotypic transformation in patients with iRBD.
[0009] Furthermore, the drug is a drug that delays the risk of neurodegenerative phenotypic transformation in patients with isolated REM sleep behavior disorder.
[0010] Furthermore, the delay in phenotypic transformation in iRBD patients is manifested in having at least one or more of the following uses: 1) Reduce the risk of neurodegenerative disease phenotypic transformation in iRBD patients; 2) Delaying the neurodegenerative clinical manifestations in iRBD patients; 3) Delay the progression of neurodegenerative biomarkers in iRBD patients.
[0011] Further, the neurodegenerative disease is an alpha-synucleinopathy-related neurodegenerative disease. Preferably, it includes at least one of Parkinson's disease (PD), dementia with Lewybodies (DLB), and multiple system atrophy (MSA). More preferably, the neurodegenerative disease is Lewy body dementia (DLB).
[0012] Further, the iRBD patients are those diagnosed by video-polysomnography (vPSG). Preferably, the iRBD patients are those diagnosed by video polysomnography and meeting the diagnostic criteria of the International Classification of Sleep Disorders, and who have not been diagnosed with PD, DLB, MSA, or other definite neurodegenerative diseases at baseline. These patients meet the diagnostic criteria for RBD at baseline, exhibiting symptoms such as loss of dystonia during REM sleep and dream enactment behavior, but have not yet been diagnosed with PD, DLB, MSA, or other definite neurodegenerative diseases. They may be RBD patients in the prodromal stage of α-synucleinopathy; or iRBD patients with a high risk of conversion to neurodegenerative diseases. iRBD patients who meet the diagnostic criteria of the International Classification of Sleep Disorders.
[0013] Furthermore, the drug comprises melatonin and pharmaceutically acceptable excipients. That is, the drug of the present invention uses melatonin as the active ingredient. The melatonin may be the sole active ingredient or may be formulated into a pharmaceutical preparation in conjunction with pharmaceutically acceptable excipients. The excipients include, but are not limited to, fillers, disintegrants, lubricants, stabilizers, sustained-release materials, controlled-release materials, flavoring agents, or coating materials.
[0014] Furthermore, the drug is an oral preparation, including but not limited to tablets, capsules, granules, sustained-release preparations, controlled-release preparations, or other pharmaceutically acceptable oral preparations.
[0015] Further, each unit dose of the drug contains 1-6 mg of melatonin. For example, the drug may be an oral capsule containing 1-6 mg of melatonin per unit dose. In a preferred embodiment, the drug is an oral capsule containing 3 mg of melatonin per unit dose. When using 3 mg capsules, a daily dose of 6 mg can be achieved by taking 2 capsules daily, a daily dose of 9 mg by taking 3 capsules daily, and a daily dose of 12 mg by taking 4 capsules daily.
[0016] Furthermore, the daily dosage of melatonin is 3 mg to 12 mg, preferably 6 mg to 12 mg. This dosage range is derived from the actual dosage distribution in a clinical follow-up cohort, as well as the results of time-dependent Cox model and penalized spline model analysis.
[0017] The drug uses melatonin as its active ingredient. Melatonin can be the sole active ingredient or it can be formulated into a pharmaceutical preparation in combination with pharmaceutically acceptable excipients. The drug is preferably an oral formulation, including but not limited to tablets, capsules, granules, sustained-release formulations, controlled-release formulations, or other pharmaceutically acceptable oral formulations. The excipients include, but are not limited to, fillers, disintegrants, lubricants, stabilizers, sustained-release materials, controlled-release materials, flavoring agents, or coating materials.
[0018] Compared with the prior art, the present invention has the following advantages: This invention provides a novel pharmaceutical use for melatonin as the active ingredient, enabling the preparation of drugs that delay the risk of phenotypic transformation in patients with isolated rapid eye movement sleep behavior disorder (iRBD), reduce the risk of phenotypic transformation in neurodegenerative diseases in iRBD patients, and especially reduce the risk of these patients developing alpha-synucleinopathy-related neurodegenerative diseases, particularly Lewy body dementia, providing a new technical solution for early drug intervention in this high-risk population of iRBD. Attached Figure Description
[0019] Figure 1 Kaplan-Meier survival curve analysis results for the risk of phenotypic transformation in iRBD patients in the continuous melatonin use group and the non-continuous melatonin use group. In the figure, PD represents Parkinson's disease and DLB represents Lewy body dementia. Figure 2 This is a graph showing the trajectory of melatonin dosage changes for each patient during the follow-up period. Each horizontal line represents a patient; the shade of blue indicates the dosage of melatonin used, with darker colors indicating higher dosages; black lines indicate no melatonin use; circles, triangles, and squares represent the progression of patients to Parkinson's disease, Lewy body dementia, and multiple system atrophy during the follow-up period, respectively. Figure 3 The results of a dose-response analysis of the time-varying melatonin dosage on the risk of phenotypic transformation; Figure 4 Propensity score distribution for patients in the unmatched and matched melatonin-using groups and the non-melatonin-using group; Figure 5 The results are from a generalized linear mixed-effects model analysis of longitudinal changes in clinical indicators related to neurodegeneration. Detailed Implementation
[0020] Overview of this study: This study included a total of 194 patients who met the diagnostic criteria for iRBD and had not been diagnosed with PD, DLB, MSA or other definite neurodegenerative diseases at baseline.
[0021] Research period: 2007–2023.
[0022] Median follow-up: 5.5 years.
[0023] Exposure definition: continuous use of melatonin for ≥1 year with coverage >50% follow-up.
[0024] Primary endpoint: Conversion to α-synucleinopathic phenotypes such as PD and DLB.
[0025] Statistical methods: Cox regression, time-varying Cox, propensity score matching, IPTW.
[0026] Key results: Overall conversion aHR 0.47; DLB conversion aHR 0.28; dose-response suggests a threshold of approximately 7 mg.
[0027] Ethics and informed consent: Approved by the Ethics Committee of the Chinese University of Hong Kong – New Territories East Cluster Clinical Research, and all patients signed written informed consent.
[0028] The following detailed description is provided through specific embodiments. Unless otherwise specified, the raw materials used in the following embodiments can be obtained from conventional commercial sources or prepared and isolated through simple synthesis; unless otherwise specified, the processes employed are conventional processes in the art.
[0029] Example 1: Study subjects, medication groups, and observation endpoints This embodiment is used to illustrate the research subjects, definition of melatonin exposure, grouping method, and observation endpoint on which this invention is based.
[0030] Referring to Table 1, this study included 194 patients with iRBD diagnosed by vPSG. All included patients met the diagnostic criteria for iRBD and had not been diagnosed with PD, DLB, MSA, or other definite neurodegenerative diseases at baseline. The mean age of the patients was 66.2 years, with a standard deviation of 7.3 years; 140 patients were male, accounting for 72.2%; the age of onset of RBD was 61.0 ± 7.8 years; the median time from onset of RBD to diagnosis was 4.3 years, with an interquartile range of 3.1–6.6 years; the median follow-up time from diagnosis was 5.5 years, with an interquartile range of 3.6–8.1 years.
[0031] Based on melatonin usage, patients were divided into a continuous use group and a non-continuous use group. The continuous use group was defined as those who used melatonin for at least one year, with the medication period covering more than 50% of the follow-up time. The non-continuous use group consisted of patients who did not meet the above criteria for continuous use. According to these criteria, the continuous use group consisted of 96 patients, and the non-continuous use group consisted of 98 patients.
[0032] Table 1 Statistical data and clinical characteristics of iRBD patients
[0033] Explanation of abbreviations in Table 1: SD: Standard Deviation; RBD: Rapid Eye Movement Sleep Behavior Disorder; IQR: Interquartile Range; RBDQ-HK: Hong Kong Version of Rapid Eye Movement Sleep Behavior Disorder Questionnaire; HADS: Hospital Anxiety and Depression Scale; ESS: Epworth Somnolence Scale; AHI: Apnea-Hypopnea Index; PLMI: Periodic Limb Movement Index; OSA: Obstructive Sleep Apnea; CPAP: Continuous Positive Airway Pressure; MoCA: Montreal Cognitive Assessment Scale; OIT: Odor Identification Test; CTT: Colored Line Test; ROCF: Ray-Oxtrieth Complex Figure Test; PPT: Purdue Pegboard Test; UPDRS-III: Unified Parkinson's Disease Rating Scale Part III.
[0034] The baseline characteristics of the two groups were generally comparable. The baseline ages of the non-continuous use group and the continuous use group were 66.2±7.9 years and 66.2±6.7 years, respectively (P=0.96); the male proportions were 72.4% and 71.9%, respectively (P=0.93); the ages at onset of RBD were 61.4±8.2 years and 60.7±7.3 years, respectively (P=0.57); the median time from onset to diagnosis of RBD was 4.1 years and 4.6 years, respectively (P=0.35); and the median follow-up time was 5.4 years and 5.7 years, respectively (P=0.54).
[0035] The medication usage patterns in the two groups are as follows: In the overall population, 174 patients (89.7%) used clonazepam; 94 patients (95.9%) used it on a non-continuous basis; and 80 patients (83.3%) used it on a continuous basis (P=0.004). The median maximum melatonin dose was 3.0 mg (interquartile range: 0.0–9.0 mg); in the non-continuous group, it was 0.0 mg (interquartile range: 0.0–3.0 mg); and in the continuous group, it was 9.0 mg (interquartile range: 6.0–12.0 mg) (P<0.001). The median maximum dose of clonazepam was 1.0 mg in both groups (P=0.81).
[0036] Most sleep and neuropsychological assessment indicators were comparable between the two groups. The RBDQ-HK scores were 43.8±16.9 and 45.6±13.7, respectively (P=0.44); the median AHI was 14.4 for both groups (P=1.00); the median PLMI was 5.8 and 6.8, respectively (P=0.33); the proportions of patients with obstructive sleep apnea were 48.0% and 47.9%, respectively (P=0.995); the proportions of patients with CPAP suppression were 43.9% and 46.9%, respectively (P=0.68); the median MoCA final scores were 25.0 and 26.0, respectively (P=0.26); and the median UPDRS-III total scores were 2.0 and 3.0, respectively (P=0.71).
[0037] The primary endpoint in this embodiment is whether the patient undergoes a neurodegenerative disease phenotypic transformation. This phenotypic transformation includes progression from iRBD to PD, DLB, or MSA. Secondary endpoints include longitudinal changes in neurodegenerative-related clinical manifestations or biomarkers, including RBDQ-HK, MoCA, CTT, FM100 Hue Test, PPT, UPDRS-III, olfactory recognition test, and other neuropsychological assessment indicators.
[0038] Example 2: Melatonin for reducing the risk of phenotypic transformation in overall neurodegenerative diseases This example illustrates the use of melatonin in the preparation of a drug for reducing the overall risk of neurodegenerative disease phenotypic transformation in patients with iRBD.
[0039] Referring to the phenotypic transformation statistics column in Table 1, among the 194 iRBD patients, 59 cases (30.4%) underwent phenotypic transformation due to neurodegenerative disease during the follow-up period. Among them, 28 cases transformed into PD (14.4%), 26 cases transformed into DLB (13.4%), and 5 cases transformed into MSA (2.6%).
[0040] In the non-continuous use group, 42 cases (42.9%) underwent overall phenotypic transformation; in the continuous use group, 17 cases (17.7%) underwent overall phenotypic transformation (P < 0.001). In other words, in this study cohort, the overall phenotypic transformation rate in the continuous use group was approximately 41.3% (17.7% / 42.9%) of the non-continuous use group.
[0041] refer to Figure 1 Kaplan-Meier survival curve analysis showed that the group that used melatonin continuously had a higher probability of not developing neurodegenerative diseases, meaning that the group that did not use melatonin continuously had a higher probability of developing neurodegenerative diseases.
[0042] Table 2. Results of Cox proportional hazards model analysis of phenotypic transformation in iRBD patients with continuous melatonin use.
[0043] In Table 2, *P<0.05; **P<0.01; ***P<0.001; bold indicates statistically significant results; Crude model: Univariate Cox regression results without adjusting for any confounding factors; Model 1: Multifactor correction adjusted for the two core confounding factors, age and gender; Model 2: Based on Model 1, the usage of clonazepam has been further corrected to further control contamination.
[0044] Referring to Table 2, the Cox proportional hazards model further showed that continued use of melatonin was associated with a reduced risk of overall neurodegenerative disease phenotypic transformation. In the unadjusted model (Crude), the overall hazard ratio for phenotypic transformation was 0.43, with a 95% confidence interval of 0.24–0.75 (P < 0.01); after adjusting for age and sex (Model 1), the hazard ratio was 0.46, with a 95% confidence interval of 0.26–0.82 (P < 0.01); after further adjusting for age, sex, and clonazepam use (Model 2), the hazard ratio was 0.47, with a 95% confidence interval of 0.26–0.83 (P < 0.01).
[0045] The above results indicate that continued use of melatonin is associated with a reduced risk of overall neurodegenerative disease phenotypic transformation in iRBD patients. Therefore, melatonin can be used to develop drugs for reducing the overall phenotypic transformation risk in iRBD patients.
[0046] Example 3: Preferred application of melatonin in reducing the risk of Lewy body dementia phenotypic transformation This embodiment illustrates a preferred embodiment of the present invention, namely the application of melatonin in the preparation of a drug for reducing the risk of iRBD patients transforming into DLB.
[0047] Based on the statistical data in Table 1, among the 194 patients, 26 developed DLB, accounting for 13.4%. Specifically, 21 patients (21.4%) in the non-continuous use group and 5 patients (5.2%) in the continuous use group (P=0.001). The DLB conversion rate in the continuous use group was approximately 24.3% (5.2% / 21.4%) of the non-continuous use group.
[0048] Cox proportional hazards model (Table 2) shows that continued use of melatonin is associated with a reduced risk of DLB conversion. In the unadjusted model (Crude), the hazard ratio for DLB conversion in the continued use group relative to the non-continued use group was 0.23, with a 95% confidence interval of 0.086–0.62 (P < 0.01). After adjusting for age and sex (Model 1), the hazard ratio was 0.28, with a 95% confidence interval of 0.10–0.76 (P < 0.05). After further adjusting for age, sex, and clonazepam use (Model 2), the hazard ratio remained at 0.28, with a 95% confidence interval of 0.10–0.76 (P < 0.05).
[0049] In comparison, for PD conversion, the conversion rates for the continuous use group and the non-continuous use group were 12.5% and 16.3%, respectively (Table 1); the hazard ratio after further adjusting for age, sex and clonazepam use (Model 2) was 0.51, with a 95% confidence interval of 0.24 to 1.10.
[0050] For MSA conversion (Table 1), there were 0 cases in the continuous use group and 5 cases in the non-continuous use group.
[0051] The above results provide more definitive data support for melatonin's ability to reduce the phenotypic risk of iRBD patients transitioning to DLB. Therefore, in a preferred embodiment of the present invention, melatonin is used to prepare a medicament for reducing the phenotypic risk of iRBD patients transitioning to DLB.
[0052] Example 4: Melatonin dose-response relationship and preferred dose range This example illustrates the dose-response relationship and preferred dose range of melatonin in reducing the risk of phenotypic transformation.
[0053] In this study, the melatonin dosage was determined based on clinical prescribing records. Referring to the statistical data in Table 1, the median maximum melatonin dose in the continuous use group was 9.0 mg, with an interquartile range of 6.0–12.0 mg; while in the non-continuous use group, the median maximum melatonin dose was 0.0 mg, with an interquartile range of 0.0–3.0 mg.
[0054] Table 3. Association analysis between melatonin use and the risk of phenotypic transformation (Cox regression model)
[0055] In Table 3, the significance rules are: *P<0.05; **P<0.01; Model 1: Crude Model without adjusting for any confounding factors. Model 2: Corrected for age and gender; Model 3: Corrected for age, sex, and clonazepam use.
[0056] To evaluate the relationship between melatonin dosage and the risk of phenotypic transformation, the inventors included melatonin dosage as a time-varying covariate in a time-dependent Cox model. Referring to Table 3, for overall neurodegenerative disease phenotypic transformation, the time-dependent Cox model showed that in the unadjusted model (Model 1), the hazard ratio was 0.90, with a 95% confidence interval of 0.84–0.97 (P < 0.01); after adjusting for age and sex (Model 2), the hazard ratio was 0.91, with a 95% confidence interval of 0.84–0.98 (P < 0.01); after further adjusting for age, sex, and clonazepam use (Model 3), the hazard ratio was 0.91, with a 95% confidence interval of 0.85–0.99 (P < 0.05).
[0057] For DLB phenotypic transformation, the time-dependent Cox model showed that the hazard ratio was 0.87 in the unadjusted model (Model 1), with a 95% confidence interval of 0.77–0.97 (P < 0.05); after adjusting for age and sex (Model 2), the hazard ratio was 0.88, with a 95% confidence interval of 0.79–0.98 (P < 0.05); after further adjusting for age, sex, and clonazepam use (Model 3), the hazard ratio was 0.88, with a 95% confidence interval of 0.79–0.99 (P < 0.05).
[0058] Figure 2 This is a trajectory graph showing the changes in melatonin dosage for each patient during the follow-up period. Each horizontal line represents a patient; the shade of blue indicates the dosage of melatonin used, with darker colors indicating higher dosages; black lines indicate no melatonin use; circles, triangles, and squares represent the progression of patients to Parkinson's disease, Lewy body dementia, and multiple system atrophy, respectively, during the follow-up period. Further analysis using a penalized spline model revealed the dose-response relationship between time-varying melatonin dosage and the risk of phenotypic transformation, with results shown below. Figure 3 As shown, the horizontal axis represents melatonin dose, and the vertical axis represents the hazard ratio for phenotypic transformation in neurodegenerative diseases. The solid line represents the dose-response curve, the shading represents the uncertainty range of the estimated value, the horizontal dashed line represents the reference line with a hazard ratio of 1, and the vertical dashed line marks the approximately 7.0 mg dose position. This suggests that a significant risk reduction trend can be observed around a melatonin dose of approximately 7.0 mg. Therefore, the daily dose of melatonin in this invention can be 3 mg to 12 mg, preferably 6 mg to 12 mg, and more preferably approximately 7 mg to 12 mg.
[0059] In one specific implementation, melatonin is administered as an oral capsule at a unit dose of 3 mg. When using this 3 mg capsule, two capsules daily provide a daily dose of 6 mg, three capsules daily provide a daily dose of 9 mg, and four capsules daily provide a daily dose of 12 mg. These dosage regimens correspond to the principal dose distribution and dose-response analysis results of the continuous use group in this study, facilitating long-term use and dose adjustment.
[0060] Example 5: Propensity score matching, inverse probability weighting, and sensitivity analysis This embodiment is used to illustrate the robustness verification of the technical effects of the present invention.
[0061] To reduce the influence of baseline confounding factors, the inventors employed propensity score matching analysis. The propensity score model included clinically relevant variables such as age, gender, education level, time from onset to diagnosis of RBD, RBDQ-HK score, clonazepam use, ESS score, AHI, MoCA score, and whether or not depression was present. Figure 4The distribution of propensity score is shown for patients in the unmatched and matched continuous melatonin use group and the non-continuous melatonin use group, illustrating the balance of baseline characteristics between the two groups after propensity score matching.
[0062] Referring to Table 3, propensity score-matched Cox regression model showed that the overall hazard ratio for neurodegenerative disease phenotype conversion in the continuous melatonin use group was 0.50 (95% confidence interval: 0.27–0.90, P < 0.05); the hazard ratio for PD conversion was 0.65 (95% confidence interval: 0.29–1.45); and the hazard ratio for DLB conversion was 0.30 (95% confidence interval: 0.11–0.82, P < 0.05).
[0063] The inventors further employed an inverse probability-weighted Cox regression model. The results showed that the overall hazard ratio for neurodegenerative disease phenotype conversion in the continuous melatonin use group was 0.52 (95% confidence interval: 0.29–0.93, P < 0.05); the hazard ratio for PD conversion was 0.95 (95% confidence interval: 0.44–2.08); and the hazard ratio for DLB conversion was 0.28 (95% confidence interval: 0.10–0.75, P < 0.05).
[0064] Table 4. Sensitivity analysis of phenotypic transformation risk in iRBD patients who continuously take melatonin under different group definitions (Cox proportional hazards model)
[0065] In Table 4, *P<0.05; **P<0.01; ***P<0.001; bold indicates statistically significant results.
[0066] To further rule out reverse causality, the inventors excluded cases of phenotypic transformation that occurred within the first two years of follow-up before conducting the analysis. The results are shown in Table 4. The overall risk of phenotypic transformation remained reduced in the group using melatonin, with an unadjusted hazard ratio of 0.46 (95% confidence interval: 0.25–0.83); the hazard ratio after adjusting for age and sex was 0.50 (95% confidence interval: 0.27–0.91); and the hazard ratio after further adjusting for age, sex, and clonazepam use was 0.50 (95% confidence interval: 0.27–0.91).
[0067] The inventors also conducted sensitivity analyses using different definitions of continuous use. When "continuous use of melatonin" was defined as coverage of follow-up time ≥25%, the hazard ratio after further adjustment for age, sex, and clonazepam use was 0.54, with a 95% confidence interval of 0.31–0.93; when defined as coverage of follow-up time ≥50%, the hazard ratio after further adjustment was 0.54, with a 95% confidence interval of 0.31–0.95; and when defined as coverage of follow-up time ≥75%, the hazard ratio after further adjustment was 0.53, with a 95% confidence interval of 0.29–0.97.
[0068] The above results demonstrate that, under different statistical analysis frameworks, different definitions of continuous medication, and after excluding early conversion events, the association between continuous use of melatonin and the reduction in overall phenotypic conversion risk and DLB conversion risk remains consistent, thus supporting the stability and reliability of the technical solution of this invention.
[0069] Example 6: Longitudinal changes in clinical indicators related to neurodegeneration This example illustrates the relationship between continuous use of melatonin and longitudinal changes in neurodegenerative clinical manifestations or biomarkers.
[0070] The inventors used a generalized linear mixed-effects model to analyze longitudinal changes in clinical indicators related to neurodegeneration. The model included follow-up time, melatonin use group, and group-time interaction term, and adjusted for age and sex. Individual patient data was used as the random intercept. Results are as follows: Figure 5 As shown in the figure, the changes in RBD symptom severity, overall cognitive function, mood, daytime sleepiness, motor function, color discrimination, sense of smell, visuospatial memory, executive function, and working memory over the follow-up period are illustrated. The RBDQ-HK (Hong Kong version of the Rapid Eye Movement Sleep Behavior Disorder Questionnaire), MoCA (Montreal Cognitive Assessment Scale), HADS (Hospital Anxiety and Depression Scale), PPT (Purdue Pegboard Test), ROCF (Ray-Osterlis Complex Figures Test), CTT (Colourne Test), OIT (Olive Interpretation Test), and DST (Digit Span Test) are also included.
[0071] The results showed that, compared with the non-continuous use group, the continuous use group of melatonin showed a slower deterioration trend in some neurodegenerative clinical indicators.
[0072] For the severity of RBD symptoms, the group-time interaction term of the RBDQ-HK score was 0.94, with a 95% confidence interval of 0.13–1.74 (P < 0.05).
[0073] For overall cognitive function, the group-time interaction term of the final MoCA score was 0.0065, with a 95% confidence interval of 0.001–0.01, P < 0.05.
[0074] For visual space and executive function related metrics, the group-time interaction term of CTT (Color Trails Test) Part 2b is -0.018, with a 95% confidence interval of -0.033 to -0.002, and P < 0.05.
[0075] For color discrimination ability, the group-time interaction term of the number of errors in the FM 100-Hue Test (Farnsworth-Munsell 100-Hue Test) was -0.020, with a 95% confidence interval of -0.022 to -0.018, P < 0.001.
[0076] For fine motor coordination, the group-time interaction term for the non-dominant hand PPT (Purdue Pegboard Test) time was -0.016, with a 95% confidence interval of -0.027 to -0.006, P < 0.01.
[0077] The above results indicate that, compared with the non-continuous use group, the continuous melatonin use group showed a slower deterioration trend in multiple neurodegenerative indicators, including RBD symptom severity, overall cognitive function, visuospatial function, color discrimination ability, and fine motor coordination. This suggests that continuous melatonin use is associated not only with a reduced risk of overall phenotypic transformation and a reduced risk of DLB transformation, but also with a slower deterioration of some neurodegenerative clinical manifestations or biomarkers. Therefore, in some embodiments of the present invention, melatonin can also be used to prepare a drug for delaying the progression of neurodegenerative clinical manifestations or biomarkers in iRBD patients.
[0078] Example 7: Implementation of Melatonin Drug Formulation This embodiment illustrates the specific implementation method of melatonin drug formulation.
[0079] In one embodiment, the drug is an oral capsule. Each capsule contains 3 mg of melatonin and pharmaceutically acceptable excipients. The excipients may include fillers, disintegrants, lubricants, stabilizers, or coating materials.
[0080] When using capsules containing 3 mg of melatonin per capsule, a daily dose of 6 mg can be achieved by taking 2 capsules daily, a daily dose of 9 mg by taking 3 capsules daily, and a daily dose of 12 mg by taking 4 capsules daily. The above dosage regimens correspond to the preferred dosage range of 6 mg to 12 mg and a further preferred dosage range of approximately 7 mg to 12 mg according to the present invention.
[0081] In another embodiment, the drug is an oral tablet. Each tablet may contain 3 mg, 5 mg, 6 mg or other suitable doses of melatonin and pharmaceutically acceptable excipients. The tablets may be formulated into daily doses of 3 mg to 12 mg, 6 mg to 12 mg or about 7 mg to 12 mg, depending on patient tolerability and risk stratification.
[0082] In another embodiment, the drug is in the form of granules. The granules are suitable for patients who have difficulty swallowing tablets or capsules, or who require flexible dosage adjustments.
[0083] In another embodiment, the drug is a sustained-release formulation. The sustained-release formulation comprises melatonin and one or more pharmaceutically acceptable sustained-release materials to achieve a more stable nighttime release of melatonin.
[0084] In another embodiment, the drug is a controlled-release formulation. The controlled-release formulation comprises melatonin and one or more pharmaceutically acceptable controlled-release materials to control the release of melatonin over a specific time period.
[0085] In some embodiments, the drug is suitable for long-term continuous use, preferably for at least 12 months, and more preferably for a duration covering more than 50% of the patient's observation or follow-up period. In some embodiments, the drug is suitable for nighttime or bedtime use to align with the characteristics of melatonin in regulating circadian rhythms and sleep-related physiological functions.
[0086] In summary, this invention utilizes melatonin to prepare a drug that delays the long-term phenotypic transformation risk of iRBD patients; it identifies target patients diagnosed by video polysomnography and without a clear baseline neurodegenerative disease; it clarifies observable endpoints such as overall phenotypic transformation, Parkinson's disease, Lewy body dementia, and multiple system atrophy; it provides specific data on the reduction in the risk of overall phenotypic transformation and the reduction in the risk of Lewy body dementia transformation in the continuous use group; it clarifies the dosage range of 6 mg to 12 mg, further optimized to approximately 7 mg to 12 mg; it clarifies the long-term medication regimen of continuous use for at least 12 months or covering more than 50% of the follow-up period; and it verifies the stability of the technical efficacy through Cox model, time-dependent Cox model, propensity score matching, inverse probability weighting, and sensitivity analysis. This provides a new early intervention strategy for iRBD, a precursor population of neurodegenerative diseases.
[0087] The embodiments described above are merely examples of several implementations of the present invention, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the present invention. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these modifications and improvements all fall within the scope of protection of the present invention.
Claims
1. The use of melatonin in the preparation of drugs for delaying the risk of phenotypic transformation in patients with isolated REM sleep behavior disorder.
2. The application according to claim 1, characterized in that, The drug is designed to delay the risk of neurodegenerative phenotypic transformation in patients with isolated REM sleep behavior disorder.
3. The application according to claim 1, characterized in that, The delay in phenotypic transformation in patients with isolated REM sleep behavior disorder is manifested in having at least one or more of the following uses: 1) Reduces the risk of neurodegenerative disease phenotypic transformation in patients with isolated REM sleep behavior disorder; 2) Delaying the neurodegenerative clinical manifestations in patients with isolated REM sleep behavior disorder; 3) Delay the progression of neurodegenerative biomarkers in patients with isolated REM sleep behavior disorder.
4. The application according to claim 3, characterized in that, The neurodegenerative disease mentioned is an alpha-synucleinosis-related neurodegenerative disease.
5. The application according to claim 4, characterized in that, The neurodegenerative diseases include at least one of Parkinson's disease, Lewy body dementia, and multiple system atrophy.
6. The application according to claim 1, characterized in that, The patients with isolated REM sleep behavior disorder are those diagnosed with isolated REM sleep behavior disorder via video polysomnography.
7. The application according to claim 1, characterized in that, The drug includes melatonin and pharmaceutically acceptable excipients.
8. The application according to claim 1, characterized in that, The drug is an oral preparation.
9. The application according to claim 8, characterized in that, Each unit dose of the drug contains 1-6 mg of melatonin.
10. The application according to claim 1, characterized in that, The daily dose of melatonin is 3 mg to 12 mg, preferably 6 mg to 12 mg, and more preferably 7 mg to 12 mg.
Citation Information
Patent Citations
Methods of treating abnormal sleep associated with loss of rapid eye movement sleep hypotension using piromelatine
CN120548180A
